<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01976416</url>
  </required_header>
  <id_info>
    <org_study_id>2012139</org_study_id>
    <nct_id>NCT01976416</nct_id>
  </id_info>
  <brief_title>Novel Use Of Hydroxyurea in an African Region With Malaria</brief_title>
  <acronym>NOHARM</acronym>
  <official_title>Novel Use Of Hydroxyurea in an African Region With Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mulago Hospital, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute
      painful episodes and reducing the need for blood transfusions in children with sickle cell
      anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan
      Africa, the areas with the most children with SCA.

      The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for
      children with SCA in a malaria endemic region within sub-Saharan Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The risk of malaria and hematologic toxicities from hydroxyurea in children with SCA living
      in malaria endemic regions is unknown.

      Some changes associated with hydroxyurea treatment (increased nitric oxide and HbF) would be
      expected to protect against malaria, but the data on hydroxyurea-related endothelial changes
      thought to be important in malaria pathogenesis (e.g. intracellular adhesion molecule
      (ICAM)-1, von Willebrand factor (VWF), tumor necrosis factor (TNF)-α) is unclear, with some
      studies suggesting that these factors might be increased with hydroxyurea and others
      suggesting no difference or a decrease.

      The specific aims of this study are as follows:

        1. Determine the incidence of malaria in children with sickle cell anemia treated with
           hydroxyurea vs. placebo

        2. Establish the frequency of hematologic toxicities and adverse events in children with
           sickle cell anemia treated with hydroxyurea vs. placebo

        3. Define the relationship between hydroxyurea treatment and fetal hemoglobin (HbF),
           soluble ICAM-1 (sICAM-1) and nitric oxide (NO) levels, and between levels of these
           factors and risk of subsequent malaria.

      Two hundred children from the Mulago Hospital Sickle Cell Clinic (MHSCC) in Kampala, Uganda
      will be randomized to receive either hydroxyurea (100) or placebo (100) at a fixed dose of 20
      ± 2.5 mg/kg/day. The primary study endpoints will be evaluated after twelve months of study
      treatment. After twelve months of study treatment, children will enter a follow-up phase
      during which they can receive an additional twelve months of open-label hydroxyurea treatment
      if they/their parents wish to do so after consultation with local physicians at the MHSCC.

      The working hypotheses of this research study are:

        1. The incidence of malaria is not greater in children with SCA treated with hydroxyurea
           than those treated with placebo

        2. Children with SCA treated with hydroxyurea will have more medication-related hematologic
           toxicities, such as neutropenia, but no increase in SCA-related adverse events (e.g.
           pain crises, hospitalizations, requirement for blood transfusion) compared to children
           treated with placebo

        3. Hydroxyurea will increase HbF and plasma NO levels and decrease plasma sICAM-1 levels;
           HbF and plasma NO levels will inversely correlate, and plasma sICAM-1 levels will
           positively correlate, with subsequent malaria incidence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Malaria Episodes</measure>
    <time_frame>12 months</time_frame>
    <description>Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <arm_group_label>Hydroxyurea</arm_group_label>
    <other_name>Siklos</other_name>
    <other_name>Hydroxycarbamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin
             electrophoresis or by peripheral blood smear showing sickled red blood cells)

          -  Age range of 1.00-3.99 years, inclusive, at the time of enrollment

          -  Weight at least 5.0 kg at the time of enrollment

          -  Willingness to comply with all study-related treatments, evaluations, and follow up

        Exclusion Criteria:

          -  Known chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis)

          -  Severe malnutrition determined by impaired growth parameters as defined by WHO (weight
             for length/height or weight-for-length/height &gt; 3 z-scores below the median WHO growth
             standards)

          -  Pre-existing severe hematological toxicity:

               1. Hb &lt;4.0 g/dL

               2. Hb &lt;6.0 g/dL AND ARC &lt;100 x 10E9/L

               3. Hb &lt;7.0 g/dL AND ARC &lt;80 x 10E9/L

               4. Platelets &lt;80 x 10E9/L

               5. ANC &lt;1.0 x 10E9/L

          -  Alanine transaminase (ALT) or creatinine &gt;2 times the upper limit of normal for age

          -  Blood transfusion within 30 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandy C. John, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mulago Hospital Sickle Cell Clinic</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <results_reference>
    <citation>Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017 Dec 14;130(24):2585-2593. doi: 10.1182/blood-2017-06-788935. Epub 2017 Oct 19.</citation>
    <PMID>29051184</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <results_first_submitted>February 2, 2018</results_first_submitted>
  <results_first_submitted_qc>February 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2018</results_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Chandy John</investigator_full_name>
    <investigator_title>Professor of Pediatrics, Medicine, Microbiology and Immunology</investigator_title>
  </responsible_party>
  <keyword>Hydroxyurea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydroxyurea</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Hydroxyurea</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydroxyurea</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Hydroxyurea</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 1.00-3.99 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Uganda</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Malaria Episodes</title>
        <description>Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydroxyurea</title>
            <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Hydroxyurea</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Malaria Episodes</title>
          <description>Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria. Incidence will be reported in the number of cases per 100 patient years.</description>
          <units>malaria episodes</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydroxyurea</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Hydroxyurea</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-Occlusive Crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Acute Splenic Squestration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="104"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-Occlusive Crisis</sub_title>
                <counts group_id="E1" events="58" subjects_affected="38" subjects_at_risk="104"/>
                <counts group_id="E2" events="106" subjects_affected="59" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E2" events="65" subjects_affected="42" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal-related</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="104"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clinical Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Other infections</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Others (e.g., injury)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="104"/>
                <counts group_id="E2" events="32" subjects_affected="24" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="107" subjects_affected="54" subjects_at_risk="104"/>
                <counts group_id="E2" events="108" subjects_affected="62" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Chandy John</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-274-8940</phone>
      <email>chjohn@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

